Skip Navigation

Related Links

Access MLPCN Resources and Related Funding Opportunities

SubMenus: MLPCN Centers | Center Capabilities | Technical Assistance | Documents & Definitions

The MLPCN resource can be accessed by any member of the scientific community in a number of ways,

If you plan to develop an HTS-ready assay you can:

  • Apply through “Development of Assays for High-Throughput Screening for Use in Probe and Pre-therapeutic Discovery (R01).

If you already have an HTS-ready assay (in 96, 384, 1536-well plate or flow cytometry) you can:

  • Obtain technical assistance in developing a high throughput screening (HTS) plan by clicking here
  • Apply through “Solicitation of Assays for High Throughput Screening (HTS) to Discover Chemical Probes” R01 and R21 funding opportunities.
  • High Throughput Screening (HTS) to Discover Chemical Probes X01 and R03.

If you have a potentially HTS-compatible assay (in test tube or 96-well plate) you can:

If you have a validated screening hiteligible for development into an in vivo chemical probe you can:

  • Apply through “Solicitation of Validated Hits for the Discovery of in vivo Chemical Probes” R01 funding opportunity

If you are a PI of an existing assay grant (R21, R01 etc)you can:

If you wish to submit compounds to the Molecular Libraries Small Molecule Repositoryyou can:

Benefits of using the MLPCN for an assay provider?

There are a number of benefits to using the MLPCN for your small molecule bioassays. Some of these are highlighted below:

  • In collaboration with an MLPCN center you can get a small molecule probe with characteristics specified in the grant proposal. This includes the primary HTS screen and follow-up cheminformatics/informatics and medicinal chemistry.
  • This is possible with completely free or minimal costs to the assay provider.
  • Get free access to one of the largest academic screening collections around. The small molecule collection includes the (possibly) largest publicly available collection of known bioactives, a range of novel chemical classes sourced from the academic community, and a diverse set of commercially available compounds.
  • The network of MLPCN centers have a broad range of expertise in different assay types and formats and scientific expertise in a range of disease biology.